API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2009
(Rs. In Lacs except per share data)
Particulars Quarter ended Quarter ended Half Year Ended Half Year Ended Year ended
30th Sep 2009 30th Sep 2008 30th Sep 2009 30th Sep 2008 31st Mar 2009
1.
(a)
(Net) Sales / Income from operations
11,968 9,414 23,167 18,800 37,650
(b) Other Operating Income - - - - -
2. Expenditure
(a)
(Increase) / Decrease in stock in trade & WIP.
(323) (1,348) (104) (1,187) 695
(b) Consumption of raw materials. 6,321 6,953 11,855 12,131 21,077
(c) Purchase of Traded Goods 2,025 670 3,755 1,520 3,443
(d) Employees cost 346 267 667 523 1,114
(e) Depreciation 334 262 662 519 1,104
(f) Other expenditure 1,726 1,475 3,160 2,778 5,648
(g) Total Expenditure 10,429 8,279 19,995 16,284 33,081
3.
Profit from Operations before Other Income, Interest & Exceptional Item
1,539 1,136 3,172 2,517 4,570
4. Other Income 29 2 31 6 17
5.
Profit before Interest & Exceptional Items
1,568 1,138 3,203 2,523 4,587
6. Interest 409 604 832 1,164 2,272
7.
Profit after Interest but before Exceptional Items
1,159 534 2,371 1,359 2,315
8. Exceptional Items - - - - -
9.
Profit from Ordinary Activities before Tax
1,159 534 2,371 1,359 2,315
10. Tax Expenses (Includes) 481 193 962 365 810
(a) Provision for Taxation 414 126 826 233 540
(b) Provision for FBT - 4 1 7 15
(c) Provision for Deffered Taxation 67 63 135 125 255
11.
Net profit from ordinary Activities after Tax
678 341 1,409 994 1,505
12.
Extraordinay Item (net of tax expenses )
- - - - -
13. Net Profit for the period 678 341 1,409 994 1,505
14.
Paid-up Equity Share Capital of Rs.10/- each.
1,171 1,171 1,711 1,171 1,171
15.
Reserves & Surplus (excluding revaluation reserves)
- - - - -
16. Basic E P S(in Rs.) 5.79 2.92 12.04 8.49 12.85
17. Public shareholding
-Number of Shares 5864219 5766044 5864219 5766044 5495949
-Percentage of Total Shareholding 50.08 49.25 50.08 49.25 46.94
18. Promoters & Promoter Group
Shareholding
(a) Pledged/Encumbered
-Number of Shares NIL N.A NIL N.A NIL
-Percentage of shares( as a percentage of the total shareholding of promoter and promoter group) NIL N.A NIL N.A NIL
-Percentage of shares( as a percentage of total sharecapital of the Company) NIL N.A NIL N.A NIL
(b) Non-encumbered
-Number of Shares 5844331 N.A 5844331 N.A 6212601
-Percentage of shares( as a percentage of the total shareholding of promoter and promoter group) 100 N.A 100 N.A 100
-Percentage of shares( as a percentage of total sharecapital of the Company) 49.92* N.A 49.92* N.A 53.06
* Reclassified

Notes :

1. The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 30th October, 2009

2. Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement as per AS - 17 'Segment Reporting' is not attracted.

3. The figures of the previous periods have been regrouped and rearranged wherever necessary.

4. Number of Investors complaints (i) pending at the beginning of quarter 1 (ii) received during the quarter : 10 (Iii) redressed : 10 (iv) pending at the end of the quarter : 1.

For and on behalf of the Board

FOR AARTI DRUGS LIMITED

Sd/-

Place : Mumbai Harshit M Savla

Date : 30th Oct, 2009 (Jt. Managing Director)

 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech